| Literature DB >> 19746976 |
Markus Nett1, Tobias A M Gulder, Andrew J Kale, Chambers C Hughes, Bradley S Moore.
Abstract
The natural proteasome inhibitor salinosporamide A from the marine bacterium Salinispora tropica is a promising drug candidate for the treatment of multiple myeloma and mantle cell lymphoma. Using a comprehensive approach that combined chemical synthesis with metabolic engineering, we generated a series of salinosporamide analogues with altered proteasome binding affinity. One of the engineered compounds is equipotent to salinosporamide A in inhibition of the chymotrypsin-like activity of the proteasome yet exhibits superior activity in the cell-based HCT-116 assay.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19746976 PMCID: PMC2771571 DOI: 10.1021/jm901098m
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446